Abstract
Psoriatic arthritis is a chronic inflammatory disease with heterogeneous manifestations (musculoskeletal and non-musculoskeletal) in patients with latent or manifest psoriasis.1 Recommendations from the European Alliance of Associations for Rheumatology (EULAR)1 published in 2019, place the use of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) as second-line treatment for the management of psoriatic arthritis, after local glucocorticoids and non-steroidal anti-inflammatory drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
